•  
  •  

Corporate

Origin

Founded 2007 (originally named Quantibact) as a spin-out from Department of Clinical Microbiology at Hvidovre University Hospital

First Step

Acquired Twisted Intercalating Nucleic Acid technology in 2007 and licensed to Eurofins and Trilink Biotechnologies for sale as a research use product

Breakthrough

Developed MeltPlex® method (2015)

Location

Located in Scion DTU Science and Technology Park

Funding

Main investor is Vecata Invest (> 80% owner)

Board

CEO is Soren Morgenthaler Echwald, an experienced molecular biologist